Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to $1.5 million.

  • Maravai Lifesciences Holdings' Change in Accured Expenses rose 243.24% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 151.84%. This contributed to the annual value of -$22.8 million for FY2024, which is 250.61% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Change in Accured Expenses is $1.5 million, which was down 74.41% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Change in Accured Expenses registered a high of $24.2 million during Q1 2023, and its lowest value of -$24.1 million during Q1 2024.
  • In the last 3 years, Maravai Lifesciences Holdings' Change in Accured Expenses had a median value of $1.5 million in 2025 and averaged $112,909.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Change in Accured Expenses spiked by 882.50% in 2022 and then slumped by 870.77% in 2023.
  • Maravai Lifesciences Holdings' Change in Accured Expenses (Quarterly) stood at $7.5 million in 2021, then plummeted by 175.11% to -$5.6 million in 2022, then skyrocketed by 209.53% to $6.1 million in 2023, then tumbled by 109.40% to -$578,000 in 2024, then surged by 243.24% to $1.5 million in 2025.
  • Its Change in Accured Expenses stands at $1.5 million for Q3 2025, versus $5.9 million for Q2 2025 and $1.5 million for Q1 2025.